EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

LRP1B Suppresses Immunotherapy Efficacy in Lung Adenocarcinoma by Preventing Ferroptosis

Zi-Hao Ke iD, Ying Chen, Tao Yu, Qi Zhang, Yan Xiang iD, Kai-Hua Lu

Cancer Medicine · 2024

DOI: 10.1002/cam4.70486 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Zi-Hao Ke und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, China. Hauptthemen laut MEDLINE: Ferroptosis, Lung Neoplasms, Adenocarcinoma of Lung, Immunotherapy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The National Natural Science Foundation of China, The Zhejiang Provincial Medical and Health Science and Technology Plan, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immune biomarkers for non‐small‐cell lung cancer (NSCLC) are programmed death ligand 1 (PD‐L1) and tumor mutational burden (TMB). However, they cannot accurately predict the effectiveness of immunotherapy. Identifying appropriate biomarkers that can differentiate between beneficiary groups is imperative.

Methods

We identified lipoprotein receptor–related protein 1B (LRP1B) mutation as a potential biomarker for immunotherapy by analyzing clinical data, combined with bioinformatics analysis. The effects of LRP1B on ferroptosis were assessed using qRT‐PCR, Western blotting, CCK‐8 assay, and flow cytometry. The potential mechanism underlying the regulation of ferroptosis by LRP1B was elucidated using qRT‐PCR, Western blotting, ChIP, and dual‐luciferase reporter gene assays.

Results

Through the collection and analysis of clinical data, we had established that LRP1B mutations are closely associated with immunotherapy. Bioinformatics analysis revealed significant differences in the expression levels of PD‐L1 and TMB between patients with LRP1B mutation and wild‐type patients in lung adenocarcinoma (LUAD). Furthermore, we observed that patients with LRP1B mutation in LUAD had significantly higher levels of tumor‐infiltrating lymphocytes (TILs) than wild‐type patients. In addition, we found that patients with LRP1B mutation in LUAD had significantly prolonged progression‐free survival (PFS) compared to wild‐type patients. However, the differences of PD‐L1 expression, TILs, and PFS were not observed in patients with LRP1B mutation in lung squamous cell carcinoma (LUSC). These findings provided strong evidence that LRP1B mutation was a potential biomarker for immunotherapy in LUAD. Moreover, our in vivo experiments indicated that knockdown of LRP1B enhanced the efficacy of mPD‐1, and mechanistic studies revealed that LRP1B regulated the sensitivity of cells to ferroptosis by modulating the expression of SLC7A11 through altering the phosphorylation level of STAT3. Further analysis revealed that LRP1B knockdown promoted immunotherapy in vivo.

Conclusions

Our results confirmed that LRP1B affected the efficacy of immunotherapy by modulating the sensitivity of NSCLC cells to ferroptosis. LRP1B mutations represent a highly promising immunotherapeutic biomarker for NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FerroptosisLung NeoplasmsAdenocarcinoma of LungImmunotherapyMutationBiomarkers, TumorHumansMiceReceptors, LDLAnimalsCell Line, TumorB7-H1 AntigenLymphocytes, Tumor-InfiltratingMaleFemaleGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

LRP1Bbiomarkerferroptosisimmunotherapylung cancer

Substanzen

LRP1B protein, humanBiomarkers, TumorReceptors, LDLB7-H1 AntigenCD274 protein, human

Autor:innen und Institutionen

  • Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, China.
  • Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
  • Medical Research Center, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, China.
  • Department of Oncology, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou, Jiangsu, China.

ORCID-Profile: Zi-Hao Ke, Yan Xiang

Förderung

  • The National Natural Science Foundation of China
  • The Zhejiang Provincial Medical and Health Science and Technology Plan
  • National Natural Science Foundation of China

Zitieren

APA

Ke, Z. H., Chen, Y., Yu, T., Zhang, Q., Xiang, Y., & Lu, K. H. (2024). LRP1B Suppresses Immunotherapy Efficacy in Lung Adenocarcinoma by Preventing Ferroptosis. Cancer Medicine. https://doi.org/10.1002/cam4.70486

Vancouver

Ke ZH, Chen Y, Yu T, Zhang Q, Xiang Y, Lu KH. LRP1B Suppresses Immunotherapy Efficacy in Lung Adenocarcinoma by Preventing Ferroptosis. Cancer Medicine. 2024. doi:10.1002/cam4.70486

BibTeX
@article{Ke2024,
  author = {Ke, Zi-Hao and Chen, Ying and Yu, Tao and Zhang, Qi and Xiang, Yan and Lu, Kai-Hua},
  title = {LRP1B Suppresses Immunotherapy Efficacy in Lung Adenocarcinoma by Preventing Ferroptosis},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.70486}
}
Kostenlos starten →